In-vitro schedule-dependent interaction between oxaliplatin and 5-fluorouracil in human gastric cancer cell lines

被引:24
作者
Qin, Baoli
Tanaka, Risa
Shibata, Yoshihiro
Arita, Shuji
Ariyama, Hiroshi
Kusaba, Hitoshi
Baba, Eishi
Harada, Mine
Nakano, Shuji
机构
[1] Kyushu Univ, Grad Sch Med, Dept Internal Med 1, Higashi Ku, Fukuoka 8128582, Japan
[2] Kyushu Univ, Grad Sch Med, Dept Biosyst Sci Med, Higashi Ku, Fukuoka 8128582, Japan
关键词
5-fluorouracil; drug interaction; oxaliplatin; schedule-dependence;
D O I
10.1097/01.cad.0000198912.98442.cd
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In order to define the most effective combination schedule of oxaliplatin (L-OHP) and 5-fluorouracil (5-FU), we investigated the in vitro interaction between these drugs in a panel of four human gastric adenocarcinoma cell lines (MKN-1, NUGC-3, NUGC-5 and AZ-521). Cytotoxic activity was determined by the WST-1 assay. Different schedules of the two drugs were compared and evaluated for synergism, additivity or antagonism with a quantitative method based on the median-effect principle of Chou and Talalay. Cell cycle perturbation and apoptosis were evaluated by flow cytometry. Simultaneous and sequential treatments of L-OHP followed by 5-FU exhibited synergistic effects in all four cell lines, whereas the reverse sequence yielded a clear antagonism. 5-FU exclusively arrested cells at the G(0)/G(1) phase, and L-OHP at the G(0)/G(1) and G2/M phases. Apoptosis was most prominent when cells were treated simultaneously or in a sequence of L-OHP? followed by 5-FU, producing apoptosis in the majority of treated cells (55.5-61.5%). In contrast, the reverse sequence yielded only 20% induction of apoptosis, the rate being not significantly different from those induced by each drug singly. Moreover, this sequence dependence was further confirmed by the experiment which compared the total number of NUGC-3 cells 7 days after these combination schedules. These findings suggest that the interaction of 5-FU and L-OHP could be highly schedule dependent, with the most efficacious interaction observed in simultaneous combination and that 5-FU followed by L-OHP would not be recommended in clinical trials for patients with advanced gastric cancer.
引用
收藏
页码:445 / 453
页数:9
相关论文
共 50 条
  • [21] Schedule-dependent synergistic effects of 5-fluorouracil and selumetinib in KRAS or BRAF mutant colon cancer models
    Jang, Hye Yeon
    Kim, Do Hyung
    Lee, Haeng Jung
    Kim, Won Dong
    Kim, Seog-Young
    Hwang, Jung Jin
    Lee, Seung Jin
    Moon, Dae Hyuk
    BIOCHEMICAL PHARMACOLOGY, 2019, 160 : 110 - 120
  • [22] In Vitro Chemosensitivity Test for Gastric Cancer Specimens Predicts Effectiveness of Oxaliplatin and 5-Fluorouracil
    Kanazawa, Yoshikazu
    Yamada, Takeshi
    Fujita, Itsuo
    Kakinuma, Daisuke
    Matsuno, Kunihiko
    Arai, Hiroki
    Shimoda, Tomohiro
    Ko, Kazuhide
    Kato, Shunji
    Matsutani, Takeshi
    Hagiwara, Nobutoshi
    Nomura, Tsutomu
    Uchida, Eiji
    ANTICANCER RESEARCH, 2017, 37 (11) : 6401 - 6405
  • [23] 5-Fluorouracil and oxaliplatin modify the expression profiles of microRNAs in human colon cancer cells in vitro
    Zhou, Jianfeng
    Zhou, Yanping
    Yin, Bin
    Hao, Wei
    Zhao, Lin
    Ju, Wenyi
    Bai, Chunmei
    ONCOLOGY REPORTS, 2010, 23 (01) : 121 - 128
  • [24] Schedule-dependent activity of 5-fluorouracil and irinotecan combination in the treatment of human colorectal cancer: in vitro evidence and a phase I dose-escalating clinical trial
    C Barone
    M Landriscina
    M Quirino
    M Basso
    C Pozzo
    G Schinzari
    G Di Leonardo
    E D'Argento
    N Trigila
    A Cassano
    British Journal of Cancer, 2007, 96 : 21 - 28
  • [25] Schedule-dependent activity of 5-fluorouracil and irinotecan combination in the treatment of human colorectal cancer:: in vitro evidence and a phase I dose-escalating clinical trial
    Barone, C.
    Landriscina, M.
    Quirino, M.
    Basso, M.
    Pozzo, C.
    Schinzari, G.
    Di Leonardo, G.
    D'Argento, E.
    Trigila, N.
    Cassano, A.
    BRITISH JOURNAL OF CANCER, 2007, 96 (01) : 21 - 28
  • [26] The effect of gefitinib (Iressa, ZD1839) in combination with oxaliplatin is schedule-dependent in colon cancer cell lines
    Xu, JM
    Azzariti, A
    Colucci, G
    Paradiso, A
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2003, 52 (06) : 442 - 448
  • [27] The effect of gefitinib (Iressa, ZD1839) in combination with oxaliplatin is schedule-dependent in colon cancer cell lines
    Jian-Ming Xu
    Amalia Azzariti
    Giuseppe Colucci
    Angelo Paradiso
    Cancer Chemotherapy and Pharmacology, 2003, 52 : 442 - 448
  • [28] ANTIPROLIFERATIVE EFFECTS OF 5-FLUOROURACIL AND OXALIPLATIN IN COLON CANCER CELL LINES: COMPARISON OF THREE DIFFERENT CYTOTOXICITY ASSAYS
    Failli, A.
    Legitimo, A.
    Orsini, G.
    Castagna, M.
    Spisni, R.
    Miccoli, P.
    Consolini, R.
    JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, 2013, 27 (01) : 275 - 284
  • [29] Schedule-dependent reversion of cisplatin resistance by 5-fluorouracil in a cisplatin-resistant human lung adenocarcinoma cell line A549DDP
    Zhan, MC
    Liu, XY
    CHINESE MEDICAL JOURNAL, 1999, 112 (04) : 336 - 339
  • [30] The Sequence-Dependent Cytotoxic Effect of Trastuzumab in Combination With 5-Fluorouracil or Cisplatin on Gastric Cancer Cell Lines
    Li, Xiao-Ling
    Yi, Shao-Qiong
    Xu, Jian-Ming
    Zhang, Yang
    Yingying-Feng
    Chen, Wei
    Song, San-Tai
    CANCER INVESTIGATION, 2010, 28 (10) : 1038 - 1047